Patent directory · USPTO A61K / A61P
Patents matching “Takeda Pharmaceutical Company Limited”
1,022 pharma patents match "Takeda Pharmaceutical Company Limited" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 1,022 pharmaceutical patents matching "Takeda Pharmaceutical Company Limited" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 11603519
T-cell receptor
granted -
US 11597928
Nucleic acid complex
granted -
US 11596688
Predicting outcome of treatment with an anti-α4β7 integrin antibody
granted -
US 11596671
Gene therapy of hemophilia B using viral vectors encoding recombinant fix variants with increased expression
granted -
US 11583563
Adeno-associated virus formulations
granted -
US 11583526
Treatment of prostate cancer
granted -
US 11584737
Heterocyclic compound
granted -
US 11576863
Formulation of an antibody and use thereof
granted -
US 11571466
Compositions and methods for treating Gaucher disease
granted -
US 11564992
Nucleophilic catalysts for oxime linkage
granted -
US 11564979
Stabilized liquid and lyophilized ADAMTS13 formulations
granted -
US 11560372
Heterocyclic compounds useful as modulators of acetylcholine receptors
granted -
US 11529363
Methods of treating cancer in pediatric patients
granted -
US 11530393
Compositions comprising iduronate-2-sulfatase
granted -
US 11529395
Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
granted -
US 11512066
Sulfonyl piperidine derivatives and their use for treating prokineticin mediated diseases
granted -
US 11505620
Methods of detecting plasma kallikrein
granted -
US 11492388
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
granted -
US 11478511
Lymphocyte biomarkers for determining the clinical response to cell therapy
granted -
US 11464869
Non-adult human dosing of brentuximab vedotin
granted -
US 11465994
MGluR7 agonist compounds for treating mGluR7-regulated diseases, disorders, or conditions
granted -
US 11459325
Heterocyclic compound
granted -
US 11453661
Heterocyclic compound
granted -
US 11447488
Heterocyclic compounds
granted